Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease?

IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Seminars in liver disease Pub Date : 2024-04-04 DOI:10.1055/s-0044-1785228
Manuel Romero-Gómez, Juan Pablo Arab, Claudia P. Oliveira, María Hernández, Marco Arrese, Helena Cortez-Pinto, Ramón Bataller
{"title":"Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease?","authors":"Manuel Romero-Gómez, Juan Pablo Arab, Claudia P. Oliveira, María Hernández, Marco Arrese, Helena Cortez-Pinto, Ramón Bataller","doi":"10.1055/s-0044-1785228","DOIUrl":null,"url":null,"abstract":"<p>Excessive alcohol consumption represents an important burden for health systems worldwide and is a major cause of liver- and cancer-related deaths. Alcohol consumption is mostly assessed by self-report that often underestimates the amount of drinking. While alcohol use disorders identification test - version C is the most widely used test for alcohol use screening, in patients with liver disease the use of alcohol biomarker could help an objective assessment. The amount of alcohol that leads to significant liver disease depends on gender, genetic background, and coexistence of comorbidities (i.e., metabolic syndrome factors). All patients with alcohol-associated liver disease are recommended to follow complete abstinence and they should be treated within multidisciplinary teams. Abstinence slows down and even reverses the progression of liver fibrosis and can help recompensate patients with complicated cirrhosis. Whether there is a safe amount of alcohol in the general population is a matter of intense debate. Large epidemiological studies showed that the safe amount of alcohol to avoid overall health-related risks is lower than expected even in the general population. Even one drink per day can increase cancer-related death. In patients with any kind of chronic liver disease, especially in those with metabolic-associated steatotic liver disease, no alcohol intake is recommended. This review article discusses the current evidence supporting the deleterious effects of small-to-moderate amounts of alcohol in the general population and in patients with underlying chronic liver disease.</p> ","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"16 1","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in liver disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/s-0044-1785228","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Excessive alcohol consumption represents an important burden for health systems worldwide and is a major cause of liver- and cancer-related deaths. Alcohol consumption is mostly assessed by self-report that often underestimates the amount of drinking. While alcohol use disorders identification test - version C is the most widely used test for alcohol use screening, in patients with liver disease the use of alcohol biomarker could help an objective assessment. The amount of alcohol that leads to significant liver disease depends on gender, genetic background, and coexistence of comorbidities (i.e., metabolic syndrome factors). All patients with alcohol-associated liver disease are recommended to follow complete abstinence and they should be treated within multidisciplinary teams. Abstinence slows down and even reverses the progression of liver fibrosis and can help recompensate patients with complicated cirrhosis. Whether there is a safe amount of alcohol in the general population is a matter of intense debate. Large epidemiological studies showed that the safe amount of alcohol to avoid overall health-related risks is lower than expected even in the general population. Even one drink per day can increase cancer-related death. In patients with any kind of chronic liver disease, especially in those with metabolic-associated steatotic liver disease, no alcohol intake is recommended. This review article discusses the current evidence supporting the deleterious effects of small-to-moderate amounts of alcohol in the general population and in patients with underlying chronic liver disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一般人群和肝病患者是否有安全的饮酒限量?
过度饮酒是全球卫生系统的一个重要负担,也是导致肝脏和癌症相关死亡的一个主要原因。酒精消耗量大多通过自我报告进行评估,但往往会低估饮酒量。虽然酒精使用障碍鉴定测试(C 版)是最广泛使用的酒精使用筛查测试,但在肝病患者中使用酒精生物标志物有助于进行客观评估。导致严重肝病的酒精量取决于性别、遗传背景和合并症(即代谢综合征因素)。建议所有酒精相关性肝病患者完全戒酒,并在多学科团队内接受治疗。戒酒可减缓甚至逆转肝纤维化的进展,有助于复杂性肝硬化患者的康复。普通人群的饮酒量是否安全是一个争论不休的问题。大型流行病学研究表明,即使在普通人群中,避免整体健康相关风险的安全饮酒量也低于预期。即使每天喝一杯酒,也会增加与癌症相关的死亡。对于任何类型的慢性肝病患者,尤其是代谢相关性脂肪肝患者,建议不要摄入酒精。这篇综述文章讨论了当前支持少量至适量酒精对普通人群和潜在慢性肝病患者产生有害影响的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Seminars in liver disease
Seminars in liver disease 医学-胃肠肝病学
CiteScore
8.20
自引率
2.40%
发文量
38
期刊介绍: Seminars in Liver Disease is a quarterly review journal that publishes issues related to the specialties of hepatology and gastroenterology. As the premiere review journal in the field, Seminars in Liver Disease provides in-depth coverage with articles and issues focusing on topics such as cirrhosis, transplantation, vascular and coagulation disorders, cytokines, hepatitis B & C, Nonalcoholic Steatosis Syndromes (NASH), pediatric liver diseases, hepatic stem cells, porphyrias as well as a myriad of other diseases related to the liver. Attention is also given to the latest developments in drug therapy along with treatment and current management techniques. Seminars in Liver Disease publishes commissioned reviews. Unsolicited reviews of an exceptional nature or original articles presenting remarkable results will be considered, but case reports will not be published.
期刊最新文献
Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease. HBV Biomarkers and Their Role in Guiding Treatment Decisions. Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease. Managing Multiorgan Failure in Acute on Chronic Liver Failure. Advancements in MELD score and its impact in Hepatology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1